Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Research & Development (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Research & Development data on record, last reported at $2.8 million in Q3 2025.

  • For Q3 2025, Research & Development rose 8.69% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $9.1 million, down 23.87%, while the annual FY2024 figure was $10.8 million, 6.33% down from the prior year.
  • Research & Development reached $2.8 million in Q3 2025 per GANX's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.4 million in Q2 2024 and bottomed at $1.2 million in Q4 2024.
  • Average Research & Development over 5 years is $2.4 million, with a median of $2.4 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 479.4% in 2021, then plummeted 48.41% in 2024.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then soared by 54.42% to $2.3 million in 2022, then grew by 4.4% to $2.4 million in 2023, then tumbled by 48.41% to $1.2 million in 2024, then surged by 132.65% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.8 million in Q3 2025, $2.8 million in Q2 2025, and $2.3 million in Q1 2025.